This is a repository copy of *Rescue and prevention in cystic fibrosis: an exploration of the impact of adherence to preventative nebulised therapy upon subsequent rescue therapy with IV antibiotics in adults with CF*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/107373/

Version: Accepted Version

**Proceedings Paper:**

https://doi.org/10.1016/S1569-1993(16)30506-9

---

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Background

The UK CF registry analysis showed that people with prior high levels of rescue will often continue to need high levels of rescue. We hypothesised that low preventative nebuliser adherence is an important predictor for rescue IV use. The UK CF registry does not record adherence data. We therefore analyse I-neb® adherence data alongside IV use data from the Sheffield Adult CF centre.

Methods

Objective adherence was calculated for those with ≥3 months of I-neb® data. Those on ivacaftor were excluded. A tree-based method (Zhang & Bracken, AJE 1996) was used to divide the study sample into clinically meaningful subgroups based on results of the UK CF registry analysis. For each subgroup, IV use in 2013 & 2014 are compared among those with adherence ≥80% vs < 80%. This cut-off for ‘good adherence’ was based on previous studies.

Results

For each clinical subgroup, people with good adherence tend to need fewer IV.

<table>
<thead>
<tr>
<th>Prior year IV ≤14 days, current FEV1 ≥70% and objective nebuliser adherence ≥80%</th>
<th>Prior year IV &lt;14 days, current FEV1 ≥70% and objective nebuliser adherence &lt;80%</th>
<th>Prior year IV &gt;14 days, current FEV1 &lt;70% and objective nebuliser adherence ≥80%</th>
<th>Prior year IV &gt;14 days, current FEV1 &lt;70% and objective nebuliser adherence &lt;80%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013: number of adults with CF</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
<tr>
<td>2013: IV days, mean (SD)</td>
<td>3.0 (5.5)</td>
<td>13.3 (13.4)</td>
<td>14 **</td>
</tr>
<tr>
<td>2013: IV days, median (IQR)</td>
<td>0 (0-7)</td>
<td>14 (0-26)</td>
<td>14 **</td>
</tr>
<tr>
<td>2014: number of adults with CF</td>
<td>10</td>
<td>23</td>
<td>1</td>
</tr>
<tr>
<td>2014: IV days, mean (SD)</td>
<td>8.0 (11.9)</td>
<td>10.4 (12.1)</td>
<td>35 **</td>
</tr>
<tr>
<td>2014: IV days, median (IQR)</td>
<td>0 (0-15)</td>
<td>10 (0-14)</td>
<td>35 **</td>
</tr>
</tbody>
</table>

[IV use by group **Unable to calculate SD / IQR]

Those with worsening FEV1 / increasing IV days resulting in worsening of their clinical subgroup from 2013 to 2014 (n=16) have lower adherence in 2013 compared to those who remained stable / improved (n=71); mean 22% (95% CI 12-33%) vs 40% (95% CI 33-47%), p-value 0.007.

Conclusion

Nebuliser adherence is an important modifiable risk factor for high IV use. Those with high IV use may benefit from better nebuliser adherence.